Immunoregulatory Role of Extracellular Vesicles in Advanced Non-Small Cell Lung Cancer

Read full text Summarise with VIRAT
Authors: Patrizia Ghidotti
Cited by: 0
References: 544

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The treatment of advanced non-small cell lung cancer (NSCLC) has greatly improved in the last decade thanks to the introduction into clinical practice of immune checkpoint blockers (ICBs), alone or in combination with chemotherapy. Despite these huge advantages, a portion of patients do not experience a benefit from ICBs. Tumor PD-L1, the only clinical available biomarker for ICB, showed limited predictive value since even low PD-L1 patients could benefit from ICB treatment. The research of a more robust and reliable biomarker represents a huge clinical need. Extracellular vesicles (EVs) for their intrinsic properties could be exploited as circulating biomarkers and considering their role in intercellular communication, they may play a role in influencing the immune response during ICB. In this thesis, EVs were investigated as possible alternative biomarkers to predict the response to ICB, used in combination with chemotherapy, in advanced stage NSCLC patients with low tumor PD-L1 levels. Furthermore, we investigated the potential immune regulatory properties of patient-derived EVs in this therapeutic setting. Starting from the comprehensive characterization of plasma EVs, we found differences in terms of both surface marker composition and microRNAs cargo in EVs isolated from Responder, Stable Disease, and Non-Responder patients. In particular, we identified 5 EV-associated features (miR-142-3p, let-7a-5p, % CD11b+, % CD63+CD11b+, %CD63+EpCAM+) that correlated with objective response rate, disease control rate, and best response of patients. The predictive value of this multiplex EV-based biomarker will be assessed in a validation cohort in the next future. Functionally, we described that miR-142-3p, enriched in Responder-EVs, could represent an important molecular player for T cell activation and functionality. Indeed, activated T cells expressed high levels of miR-142-3p and concomitantly produced EVs enriched with miR-142-3p. Interestingly, the transfection of T cells with miR-142-3p mimic induced a higher production of IFNγ in CD8+ T cells. However, when T cells were co-cultured with patient-derived EVs, we did not observe any modulation in terms of both T cell proliferation and functionality. Moreover, in our experimental conditions, miR-142-3p did not induce chemotherapy sensitization in NSCLC cells when treated with cisplatin. Our data suggest the use of EV-associated features as predictive biomarkers in in context of ICB used in combination with chemotherapy. Instead, whether a specific subpopulation of circulating patient-derived EVs take part in T cell regulation and whether such regulation may influence response to combination therapy is still to be determined.

Fields of Study & Subjects

Extracellular vesicles in disease Cancer Immunotherapy and Biomarkers MicroRNA in disease regulation

Publication details

Journal / source
Open Research Online (The Open University)
Publication date
1 January 2026
Language
EN
Document type
Thesis